Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates
详细信息 查看全文
- 作者：Michael J. McCluskiea ; michael.mccluskie@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Jennifer Thornb ; David P. Gervaisc ; 1 ; David R. Steadc ; Ningli Zhanga ; Michelle Benoita ; Janna Cartiera ; In-Jeong Kima ; Keshab Bhattacharyab ; Jari I. Finnemanb ; James R. Mersonc ; Heather L. Davisa
- 刊名：International Immunopharmacology
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：29
- 期：2
- 页码：663-671
- 全文大小：805 K
文摘
- •
Anti-nicotine vaccine optimized for antigen & adjuvant tested in non-human primates
- •
Vaccine comprised nicotine conjugated to CRM197 (NIC7-CRM) with alum ± CpG.
- •
NIC7-CRM/alum was better than a NicQb mimetic (with alum) for Ab titer and function.
- •
Addition of CpG to NIC7-CRM significantly enhanced Ab titer, avidity and function.